echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > How do R&D biopharmaceutical companies cope with the challenge of tight cash flow?

    How do R&D biopharmaceutical companies cope with the challenge of tight cash flow?

    • Last Update: 2022-09-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    At the time of the financing winter, VC/PE investment is more cautious, and the overall market in the secondary market is in a turbulent adjustment stage


    Listed companies: Plan ahead for early financing

    Listed companies: Plan ahead for early financing

    Among the listed biomedical companies, many may have products on the market, but the sales of the products are still small and still not profitable; Or there are no products on the market, but multiple products are in the late stages of clinical research, or clinical trials have been completed and submitted to the NDA for approval


    These companies are still in the "burning money" stage, and there is still a year to go before they become profitable


    Hundreds of biomedical companies in the United States have gone through such a process, and achieving profitability usually requires at least 10 years of arduous process


    PIPE is often based on the company's stock price at that time, financing needs, scale and use, as well as additional conditions, debt-to-equity swaps, interest and discounted prices, etc.


    At present, for biotechnology companies that are not yet profitable, under the premise of compliance, they can try to do follow-up financing


    Unlisted companies: Priority will be given to key projects

    Unlisted companies: Priority will be given to key projects

    For unlisted biomedical R&D companies, facing the unfavorable environment of capital winter, declining valuation and financing difficulties, it is first necessary to study and analyze the company's financial situation and project funding needs, and must control expenses and cash flow, and do not arbitrarily expand expenditures


    For research projects, it is necessary to consider


    Whether it is a listed or unlisted biotechnology company, when the capital winter financing is difficult and the valuation is declining, the management must adjust its mentality, keep an eye on the money bag, and use the money on the


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.